{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:02:28Z","timestamp":1784901748584,"version":"3.55.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:00:00Z","timestamp":1783209600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Medytox"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Submental fat (SMF) is commonly treated with liposuction, surgery, or injectable drugs. Cholic acid, a primary bile acid, can induce lipolysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the efficacy and safety of MT921, an injectable cholic acid formulation, for reducing moderate-to-severe SMF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with moderate-to-severe SMF were randomized to receive MT921 1.0%\/1.0\u2005cm, MT921 1.5%\/1.0\u2005cm, MT921 1.5%\/1.25\u2005cm, or placebo. Primary endpoints were \u22651- and \u22652-grade improvements in clinician- and patient-assessed SMF rating scales (SMFRSs) at 4 weeks after the final treatment. Secondary endpoints included changes in SMFRS, patient satisfaction, patient-assessed SMF impact scale (PA-SMFIS), and SMF volume or thickness measured by MRI or calipers. Safety was assessed by adverse events, laboratory tests, and vital signs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In Groups 1, 2, 3, and 4, respectively, \u22651-grade improvement in clinician-assessed SMFRS was achieved by 72.73%, 88.64%, 79.07%, and 48.78% of patients, and \u22651-grade improvement in patient-assessed SMFRS by 77.27%, 88.64%, 79.07%, and 46.34%. Compared with placebo, MT921 showed favorable improvements in SMFRS responses, patient satisfaction, PA-SMFIS, and caliper-measured SMF thickness. MRI-measured SMF volume decreased in MT921-treated groups but not in the placebo group. Adverse events were more frequent with MT921 but were mostly mild or moderate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MT921 showed favorable efficacy signals for reducing moderate-to-severe SMF and was generally well tolerated. These findings support further evaluation of MT921, particularly the 1.5% formulation, in larger Phase 3 trials with longer follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence: 1 (Therapeutic)<\/jats:title>\n                    <jats:p>For image description, please refer to the figure legend and surrounding text.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/asj\/sjag136","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:48:03Z","timestamp":1783082883000},"source":"Crossref","is-referenced-by-count":0,"title":["A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Parallel, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MT921 in Patients with Moderate-to-Severe Submental Fat"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7709-5384","authenticated-orcid":false,"given":"Si-Hyung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Shun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Kyung","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bark-Lynn","family":"Lew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4720-9955","authenticated-orcid":false,"given":"Sang Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Soo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weon Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwang Seong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,5]]},"reference":[{"key":"2026072409124931400_sjag136-B1","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1097\/01.prs.0000209406.80690.9f","article-title":"Neck rejuvenation revisited","volume":"118","author":"Rohrich","year":"2006","journal-title":"Plast Reconstr Surg"},{"key":"2026072409124931400_sjag136-B2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.fsc.2009.07.001","article-title":"Rejuvenation of the aging neck: current principles, techniques, and newer modifications","volume":"17","author":"Caplin","year":"2009","journal-title":"Facial Plast Surg Clin North Am"},{"key":"2026072409124931400_sjag136-B3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/PRS.0b013e3182958b6f","article-title":"Five-step neck lift: integrating anatomy with clinical practice to optimize results","volume":"132","author":"Narasimhan","year":"2013","journal-title":"Plast Reconstr Surg"},{"key":"2026072409124931400_sjag136-B4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.coms.2008.10.008","article-title":"Complications of neck liposuction and submentoplasty","volume":"21","author":"Koehler","year":"2009","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"2026072409124931400_sjag136-B5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1055\/s-0032-1305793","article-title":"Lower face-lift with extensive neck recontouring","volume":"28","author":"Langsdon","year":"2012","journal-title":"Facial Plast Surg"},{"key":"2026072409124931400_sjag136-B6","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/j.1524-4725.2010.01566.x","article-title":"Tissue-selective effects of injected deoxycholate","volume":"36","author":"Thuangtong","year":"2010","journal-title":"Dermatol Surg"},{"key":"2026072409124931400_sjag136-B7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1524-4725.2006.33036.x","article-title":"Action of sodium deoxycholate on subcutaneous human tissue: local and systemic effects","volume":"33","author":"Yagima Odo","year":"2007","journal-title":"Dermatol Surg"},{"key":"2026072409124931400_sjag136-B8","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.jaad.2016.04.028","article-title":"ATX-101 for reduction of submental fat: a phase III randomized controlled trial","volume":"75","author":"Humphrey","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2026072409124931400_sjag136-B9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/DSS.0000000000000578","article-title":"REFINE-1, a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial with ATX-101, an injectable drug for submental fat reduction","volume":"42","author":"Jones","year":"2016","journal-title":"Dermatol Surg"},{"key":"2026072409124931400_sjag136-B10","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1097\/DSS.0000000000002318","article-title":"Adverse events of injectable deoxycholic acid","volume":"46","author":"Pham","year":"2020","journal-title":"Dermatol Surg"},{"key":"2026072409124931400_sjag136-B11","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S0022-2275(20)42614-8","article-title":"Bile acid structure-activity relationship: evaluation of bile acid lipophilicity using 1-octanol\/water partition coefficient and reverse phase HPLC","volume":"31","author":"Roda","year":"1990","journal-title":"J Lipid Res"},{"key":"2026072409124931400_sjag136-B12","doi-asserted-by":"publisher","DOI":"10.3390\/ph14070654","article-title":"Evaluation for potential drug-drug interaction of MT921 using in vitro studies and physiologically-based pharmacokinetic models","volume":"14","author":"Ryu","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026072409124931400_sjag136-B13","doi-asserted-by":"publisher","DOI":"10.3390\/ph14080830","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of cholic acid (MT921) after a subcutaneous injection in the submental area to humans","volume":"14","author":"Chung","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026072409124931400_sjag136-B14","doi-asserted-by":"publisher","first-page":"G327","DOI":"10.1152\/ajpgi.00093.2007","article-title":"Differential regulation of cyclin D1 and cell death by bile acids in primary rat hepatocytes","volume":"293","author":"Castro","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2026072409124931400_sjag136-B15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1006\/taap.2000.8894","article-title":"Glutathione status of isolated rat hepatocytes affects bile acid-induced cellular necrosis but not apoptosis","volume":"164","author":"Gumpricht","year":"2000","journal-title":"Toxicol Appl Pharmacol"},{"key":"2026072409124931400_sjag136-B16","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd8019","article-title":"Biodegradable, bile salt microparticles for localized fat dissolution","volume":"6","author":"Safari","year":"2020","journal-title":"Sci Adv"},{"key":"2026072409124931400_sjag136-B17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.12788\/j.sder.2015.0175","article-title":"Additional thoughts on the new treatment Kybella","volume":"34","author":"Cohen","year":"2015","journal-title":"Semin Cutan Med Surg"}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjag136\/68697364\/sjag136.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjag136\/68697364\/sjag136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:12:52Z","timestamp":1784898772000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/advance-article\/doi\/10.1093\/asj\/sjag136\/8724950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,5]]},"references-count":17,"URL":"https:\/\/doi.org\/10.1093\/asj\/sjag136","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"value":"1090-820X","type":"print"},{"value":"1527-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,5]]},"article-number":"sjag136"}}